Search results for "tips"

showing 10 items of 280 documents

Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study

2009

AbstractObjectiveTo examine the predictive validity of early improvement in a naturalistic sample of inpatients and to identify the criterion that best defines early improvement.MethodsTwo hundred and forty-seven inpatients who fulfilled ICD-10 criteria for schizophrenia were assessed with the Positive And Negative Syndrome Scale (PANSS) at admission and at biweekly intervals until discharge from hospital. Remission was defined according to the recently proposed consensus criteria, response as a reduction of at least 40% in the PANNS total score from admission to discharge.ResultsReceiver operating characteristic (ROC) analyses showed that early improvement (reduction of the PANSS total sco…

AdultMalePredictive validitymedicine.medical_specialtyDrug trialAdolescentmedicine.medical_treatmentConsensus criteriaSensitivity and SpecificitySeverity of Illness Index03 medical and health sciences0302 clinical medicineNaturalistic observationInternational Classification of DiseasesInternal medicinemedicineHumans030212 general & internal medicinePsychiatryAntipsychoticAgedPsychiatric Status Rating ScalesPositive and Negative Syndrome ScaleReceiver operating characteristicPatient SelectionMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTranquilizing AgentsTreatment OutcomeROC CurveSchizophreniaArea Under CurveSchizophreniaFemalePsychologyAntipsychotic AgentsFollow-Up StudiesEuropean Psychiatry
researchProduct

Savoxepine: invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patien…

1991

The new tetracyclic compound savoxepine exhibits potent antidopaminergic effects with preferential activity in the hippocampus as compared to striatum in rat brain. As a result of behavioural animal models and regional differences in dopamine receptor binding characteristics, it has been suggested to possess an "atypical" neuroleptic response pattern. In an open clinical trial, savoxepine was administered to 12 in-patients suffering from paranoid schizophrenia and schizophreniform disorder (DSM-III). Eight patients were treated with a stable dose of 0.5 mg per day throughout the study, while in the remaining patients higher doses up to 20 mg/day were administered. Mean total BPRS scores and…

AdultMalePsychosisParanoid schizophreniamedicine.medical_treatmentPharmacologyExtrapyramidal symptomsBasal Ganglia DiseasesmedicineHumansSchizophreniform disorderAntipsychoticAgedPharmacologyPsychiatric Status Rating ScalesDopamine antagonistDopamine receptor bindingMiddle Agedmedicine.diseaseEnzymesDisease Models AnimalSchizophreniaDibenzoxazepinesSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychologymedicine.drugAntipsychotic AgentsPsychopharmacology
researchProduct

Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed?

2000

SummaryIn this multicentre study the two-year outcome of two groups of consecutive patients (total N = 106) with first-episode functional non-affective psychosis, both treated according to the ‘need-specific Finnish model’, which stresses teamwork, patient and family participation and basic psychotherapeutic attitudes, was compared. No alternative treatment facilities were available in the study sites. The two study groups differed in the use of neuroleptics: three of the sites (the experimental group) used a minimal neuroleptic regime whilst the other three (the control group) used neuroleptics according to the usual practice. Total time spent in hospital, occurrence of psychotic symptoms …

AdultMalePsychosismedicine.medical_specialtyAdolescentChlorpromazine050109 social psychologyOutcome (game theory)Catchment Area HealthmedicineHumansPsychiatric hospital0501 psychology and cognitive sciencesPsychiatryFinlandPatient Care Teambusiness.industryPublic health05 social sciences050301 educationSocial environmentMiddle Agedmedicine.diseaseMental healthClinical trialPsychiatry and Mental healthTreatment OutcomePsychotic DisordersPhysical therapyFemalebusinessAttitude to Health0503 educationPsychosocialAntipsychotic AgentsEuropean Psychiatry
researchProduct

Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFI…

2013

Abstract Objective Predicting response to antipsychotic treatment might optimize treatment strategies in early phases of schizophrenia. We aimed to investigate sociodemographic, premorbid and clinical predictors of response to antipsychotic treatment after a first episode of non-affective psychosis. Method 375 (216 males) patients with a diagnosis of non affective psychosis entered the study. The main outcome measure was clinical response at 6 weeks and variables at baseline were evaluated as predictors of response. ANOVA for continuous and chi-square for categorical data were used to compare responders and non-responders. Multivariate logistic regression was used to establish a prediction …

AdultMalePsychosismedicine.medical_specialtyAdolescentLogistic regressionCohort StudiesYoung AdultPredictive Value of TestsOutcome Assessment Health CaremedicineHumansFamily historyPsychiatryBiological PsychiatryRetrospective StudiesPharmacologyFirst episodePsychiatric Status Rating ScalesAnalysis of VarianceChi-Square DistributionMiddle Agedmedicine.diseaseLogistic ModelsPsychotic DisordersSchizophreniaSpainCohortdupFemalePsychologyDiagnosis of schizophreniaAntipsychotic AgentsProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis.

2018

Background: Hyperprolactinemia is a common side-effect of antipsychotics (APs), which may trigger serious secondary problems and compromise the adherence to treatment which is crucial for prognosis, especially in patients presenting with a first-episode of psychosis (FEP). Aims: We evaluated, in some cases for the first time, the effect of polymorphisms in multiple candidate genes on serum prolactin (PRL) levels in an AP-treated FEP cohort recruited in the multicenter PEPs study (Phenotype − genotype and environmental interaction; Application of a predictive model in first psychotic episodes). Methods: PRL concentration was measured in serum from 222 patients. A total of 167 polymorphisms w…

AdultMalePsychosismedicine.medical_specialtyCandidate geneSerotoninSide effectAdolescentmedicine.medical_treatmentDopaminePeptidyl-Dipeptidase A03 medical and health sciencesYoung Adult0302 clinical medicineDopaminePolymorphism (computer science)Internal medicinemedicineHumansReceptor trkBPharmacology (medical)AntipsychoticPharmacologyMembrane GlycoproteinsPolymorphism Geneticbusiness.industryReceptors Dopamine D2medicine.diseaseProlactin030227 psychiatryProlactinHyperprolactinemiaPsychiatry and Mental healthEndocrinologyPsychotic DisordersCohortFemalebusiness030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsJournal of psychopharmacology (Oxford, England)
researchProduct

Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and cha…

1995

Preclinical data indicated that seroquel (ICI 204 636), a dibenzothiazepine with 5-HT2 and D2-like receptor antagonistic properties, might be an effective antipsychotic agent, causing fewer extrapyramidal side effects than typical neuroleptics. In the present study, 12 patients suffering from schizophrenia or schizophreniform disorder with predominantly positive symptomatology were treated in an open clinical trial for 4 weeks with seroquel at a maximum dosage of 750 mg/day. The drug was generally well tolerated, and virtually no adverse extrapyramidal side effects such as acute dystonia, parkinsonism or akathisia were observed. Total scores for BPRS (item score 0–6; baseline: 42.0±2.3; mea…

AdultMalePsychosismedicine.medical_specialtyDibenzothiazepinesTime Factorsmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticThyrotropinAkathisiaGastroenterologyQuetiapine FumarateAntipsychotic AgentInternal medicinemedicineHumansSchizophreniform disorderAntipsychoticAgedPharmacologyPsychiatric Status Rating ScalesParkinsonismElectroencephalographyMiddle Agedmedicine.diseaseProlactinTreatment OutcomeSchizophreniaAnesthesiaSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychologyAntipsychotic AgentsPsychopharmacology
researchProduct

The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: A 3 year …

2013

Real-world functional deficits are common and persistent in individuals with psychosis. Cognitive deficits have been shown to compromise functioning. We aimed to study the predictive values of premorbid, sociodemographic, and baseline clinical and neurocognitive factors on long-term functional outcome for individuals with first episode non-affective psychosis. We failed to demonstrate a significant relationship between cognitive deficits at baseline and functional disability at 3 year follow-up. Diagnosis of schizophrenia (OR=2.457, p=0.011), shorter education (OR=1.177, p=0.005) and poor premorbid social adjustment (OR=1.628, p=0.013) emerged as the strongest predictors for the 114 subject…

AdultMalePsychosismedicine.medical_specialtyLongitudinal studyAdolescentNeuropsychological TestsOutcome (game theory)Disability EvaluationYoung AdultPredictive Value of TestsmedicineHumansLongitudinal StudiesPsychiatryBiological PsychiatryRetrospective StudiesFirst episodeCognitionMiddle AgedPrognosismedicine.diseasePsychiatry and Mental healthLogistic ModelsPsychotic DisordersSocioeconomic FactorsSchizophreniaFemaleCognition DisordersPsychologyNeurocognitiveAntipsychotic AgentsDiagnosis of schizophreniaPsychiatry Research
researchProduct

Duration of active psychosis and functional outcomes in first-episode non-affective psychosis.

2018

AbstractBackground:The duration of untreated psychosis (DUP) has been associated with negative outcomes in psychosis; however, few studies have focused on the duration of active psychotic symptoms after commencing treatment (DAT). In this study, we aimed to evaluate the effect of DUP and DAT on functional long-term outcomes (3 years) in patients with early psychosis.Methods:We evaluated the Scale for the Assessment of Positive Symptoms (SAPS) at frequent intervals for 3 years after presentation to determine the DAT for 307 individuals with first-episode psychosis together with DUP and clinical variables. The functional outcomes were assessed using the Disability Assessment Scale (DAS) at th…

AdultMalePsychosismedicine.medical_specialtyTime FactorsLogistic regressionCohort Studies03 medical and health sciencesDisability Evaluation0302 clinical medicineActivities of Daily LivingmedicineHumansProspective StudiesPsychiatryProspective cohort studyFirst episodePsychiatric Status Rating ScalesReceiver operating characteristicbusiness.industrymedicine.disease030227 psychiatryPsychiatry and Mental healthTreatment OutcomePsychotic DisordersSchizophreniaNon affective psychosisdupSchizophreniaFemaleSchizophrenic PsychologybusinessSocial Adjustment030217 neurology & neurosurgeryAntipsychotic AgentsEuropean psychiatry : the journal of the Association of European Psychiatrists
researchProduct

Experience of Psychotropic Medication -An Interview Study of Persons with Psychosis.

2016

Psychotropic drugs, particularly antipsychotic types, are a cornerstone of the treatment of people with psychosis. Despite numerous studies showing that drug treatment with psychotropic drugs initially alleviates psychiatric symptoms, the proportion of people with mental health problems and symptoms that do not follow doctors' prescriptions, thus exhibiting so-called non-adherence, is considerable. Non-adherence is predominantly seen as a clinical feature and as a patient characteristic that is especially due to patients' poor understanding that they are ill. There is also a widespread notion that non-adherence is of great disadvantage to the patient. This article is based on interviews wit…

AdultMalePsychosismedicine.medical_specialtymedicine.medical_treatmentMedication adherencePsychotropic medicationMedication Adherence03 medical and health sciencesDrug treatmentYoung Adult0302 clinical medicinemedicineHumans030212 general & internal medicineYoung adultPatient participationAntipsychoticPsychiatryAgedPsychotropic Drugsbusiness.industryPatient PreferenceMiddle Agedmedicine.disease030227 psychiatryPsychotic DisordersInterview studyFemalePshychiatric Mental HealthPatient ParticipationbusinessClinical psychologyIssues in mental health nursing
researchProduct

The applicability of SRTM in [18F]fallypride PET investigations: Impact of scan durations

2011

The high-affinity radioligand [18F]fallypride (FP) is frequently used for quantification of striatal/extrastriatal D2/3 receptors and the receptor occupancies of antipsychotics (APs). Its 110 minutes half-life allows long scan durations. However, the optimum scan duration is a matter of debate. This investigation focuses on scan-duration-related effects on simplified reference tissue model (SRTM) results and the time point of transient equilibrium in a large sample of dynamic FP positron emission tomography (PET) scans. Fifty drug-free and 50 AP-treated subjects underwent FP-PET scans (180 minutes scan duration). The binding potential ( BPND) of the putamen, thalamus, and temporal cortex w…

AdultMalePyrrolidinesTime FactorsMaterials scienceAdolescentShuttle Radar Topography MissionRadioligand AssayYoung AdultRadioligandmedicineHumansTemporal cortexTransient equilibriummedicine.diagnostic_testReceptors Dopamine D2business.industryMental DisordersPutamenReceptors Dopamine D3Binding potentialMiddle AgedCorpus StriatumNeurologyFallypridePositron emission tomographyPositron-Emission TomographyBenzamidesFemaleOriginal ArticleNeurology (clinical)Cardiology and Cardiovascular MedicineNuclear medicinebusinessAntipsychotic AgentsJournal of Cerebral Blood Flow & Metabolism
researchProduct